



Gothenburg, 05 July 2017

PRESS RELEASE FLUICELL AB

## **SWEDISH BIOTECH FLUICELL AB SHINES IN PRIVATE PLACEMENT ROUND REACHING CLOSE TO 300% OVERSUBSCRIPTION RATE**

Fluicell AB is pleased to announce the closing of 8MSEK private placement round in April 2017 that reached an oversubscription rate of 300%.

“We are honored by the great interest shown for Fluicell’s growth potential during the private placement and we thank InWest Corporate Finance AB and Roger Lundin for their assistance during the process” says Victoire Viannay, CEO of Fluicell AB.

The company prepares for a stock market listing later this year, and the proceeds from this investment will be used for key people recruitments as well as to expand and complement current product offerings with a continued focus on transformative single-cell biology, and bioprinting technologies.

### **About Fluicell**

*Fluicell is a Swedish biotech company that brings inspiration and innovation to life-science researchers around the globe. Fluicell provides innovative tools with outstanding performance, redefining approaches within; cell biology, biophysics and secondary drug screening and discovery. Fluicell strives for technology solutions which are environmentally friendly, sustainable,*

*and that ultimately reduces costs, resources, and minimizes the use of animals. Flucell's main target sectors include universities, the pharmaceutical industry, and national health laboratories.*

For further information, visit [www.flucell.com](http://www.flucell.com) or contact:

Victoire Viannay CEO, Flucell

Email: [victoire@flucell.com](mailto:victoire@flucell.com)